TORONTO, ON / ACCESSWIRE / August 14, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three and six months ended June 30, 2019 and provided an update on its business.

During the quarter, Edesa completed its reverse acquisition and Nasdaq listing, and announced plans to proceed with its clinical investigation of EB01, a novel sPLA2 inhibitor, which the company is developing as a potential treatment for chronic allergic contact dermatitis (ACD). Edesa is currently performing site initiation visits at investigational centers in the U.S. and expects to proceed with enrolling the first patient into its Phase 2b clinical trial in the current quarter.

"Our first quarter as a public company has been very productive and I am pleased to report that our team has maintained a rapid pace toward the initiation of our Phase 2b clinical study of EB01," said Dr. Par Nijhawan, Chief Executive Officer of Edesa. 'The next few quarters will be an exciting time for Edesa as we expect to enroll our first EB01 patient, expand the utility of our sPLA2 anti-inflammatory technology into additional indications and evaluate additional assets that can provide new value creation opportunities."

Edesa's Chief Financial Officer, Kathi Niffenegger, reported that the combined company's working capital at the end of the fiscal quarter was higher than projected. "Our working capital benefited from lower than expected acquisition-related costs as well as steps taken by management to conserve cash during the transaction. As a result, we are well positioned to support our current clinical plans and activities," she said.

Financial Results

Three months ended June 30, 2019

Total revenues were not material for the three months ended June 30, 2019 and June 30, 2018 as the company continued to focus on developing and obtaining regulatory approval for its product candidates.

Total operating expenses increased by $0.90 million to $1.32 million for the three months ended June 30, 2019 compared to $0.42 million for the same period last year:

• Research and development expenses increased by $0.20 million to $0.50 million for the three months ended June 30, 2019 compared to $0.30 million for the same period last year primarily due to an increase in clinical research expenses associated with the Phase 2B clinical study of Edesa's EB01 product candidate as well as higher personnel expenses.
• General and administrative expenses increased by $0.70 million to $0.82 million for the three months ended June 30, 2019 compared to $0.12 million for the same period last year primarily due to increased legal and professional fees related to the company's reverse acquisition, increased personnel expenses and the initiation of public company expenses, which Edesa did not incur as a privately held company.

Net loss for the three months ended June 30, 2019 was $1.29 million, or $0.30 per basic share, compared to a net loss of $0.41 million, or $0.13 per basic share, for the three months ended June 30, 2018.

Six months ended June 30, 2019

Total revenues were not material for the six months ended June 30, 2019 and June 30, 2018.

Total operating expenses increased by $1.01 million to $1.86 million for the six months ended June 30, 2019 compared to $0.85 million for the same period last year:

• Research and development expenses increased by $0.03 million to $0.61 million for the six months ended June 30, 2019 compared to $0.58 million for the same period last year primarily due to an increase in clinical research expenses associated with the Phase 2B clinical study of Edesa's EB01 product candidate as well as higher patent fees and personnel expenses.
• General and administrative expenses increased by $0.97 million to $1.25 million for the six months ended June 30, 2019 compared to $0.28 million for the same period last year primarily due to increased legal and professional fees related to the company's reverse acquisition, increased personnel expenses and the initiation of public company expenses, which Edesa did not incur as a privately held company.

Net loss for the six months ended June 30, 2019 was $1.82 million, or $0.48 per basic share, compared to a net loss of $0.83 million, or $0.26 per basic share, for the six months ended June 30, 2018.

Edesa changed its year end from December 31 to September 30 resulting in six months activity during this transitional period through June 30, 2019.

Working Capital

At June 30, 2019, the company had working capital of $6.11 million. Cash and cash equivalents totaled $6.36 million.

Investor Calendar

The company is scheduled to present at the H.C. Wainwright & Co. 21st Annual Global Investment Conference, September 8-10, 2019 in New York, NY. Management will also be attending the BIO Investor Forum in San Francisco, October 22-23, 2019. Investors interested in meetings with management can schedule through the conference meeting systems, or by contacting Edesa investors relations at investors@edesabiotech.com

About Edesa Biotech, Inc.

Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company focused on efficiently developing innovative treatments that address significant unmet medical needs. Edesa's lead product candidate, EB01, is a novel non-steroidal anti-inflammatory molecule (sPLA2 inhibitor) for the treatment of chronic allergic contact dermatitis which has demonstrated statistically significant improvements in multiple clinical studies. Edesa also intends to expand the utility of its sPLA2 inhibitor technology, which forms the basis for EB01, across multiple indications and expand its portfolio with assets that can drive long-term growth opportunities. The company is based in Markham, Ontario, Canada, with U.S. offices in Southern California.

Edesa Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as 'anticipate,' 'believe,' 'plan,' 'estimate,' 'expect,' 'intend,' 'may,' 'will,' 'would,' 'could,' 'should,' 'might,' 'potential,' or 'continue' and variations or similar expressions, including statements related to: the company's commitment to rapidly advance its clinical plans and in the next few quarters enroll its first EB01 patient, expand the utility of its sPLA2 anti-inflammatory technology into additional indications and evaluate additional assets that can provide new value creation opportunities. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property and the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.

Contacts
Gary Koppenjan
Edesa Biotech, Inc.
(805) 488-2800
investors@edesabiotech.com

Condensed Interim Consolidated Statements of Operations
(Unaudited)

Condensed Interim Consolidated Balance Sheets
(Unaudited)

		June 30,				December 31,
		2019				2018
Cash and cash equivalents		$	6,363,096			$	3,367,098
Accounts and other receivable			345,014			$	7,339
Inventory			77,913			$	-
Prepaid expenses and deposits			337,668				16,487
Noncurrent assets			103,929				7,386
Total Assets		$	7,227,620			$	3,398,310
				Share article: Watch latest videos Subscribe and Follow Get a daily dose of The US News news through our daily email, its complimentary and keeps you fully up to date with world and business news as well. Subscribe Now News RELEASES Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to The US News. More Information 38 ℉ Mostly Cloudy in Wenatchee International Section Haitian leaders called on to reverse country's downfall NEW YORK, New York - Leaders in Haiti must step up and end the political impasse between President Jovenel Mose ... Delving in among the smoke and mirrors of the Pell case Compound Probability and the CrownIn his appeal to the Intermediate Court, Bret Walker referred to 13 solid obstacles that pointed ... Bayrob hackers infected 400,000 computers before being taken down The hackers were like modern-day John Dillingers, brazenly committing their crimes and repeatedly escaping law enforcement's grasp.But like Dillinger and ... Upbeat Chinese FM says virus control efforts 'are working' China's efforts to control the deadly outbreak of a new coronavirus "are working", Beijing's top diplomat said Thursday, attributing an ... Coronavirus more closely aligned to flu than other viruses CHICAGO, Illinois - Scientists in China who studied the nose and throat swabs from 18 patients infected with the new ... Roger Stone gets 3 years and four months prison sentence WASHINGTON, DC - A federal judge on Thursday sentenced President Donald Trump's longtime confidant Roger Stone to 40 months in ... Business Section Wall Street and the dollar drop sharply, world markets follow NEW YORK, New York - U.S. stocks fell sharply on Friday as profit-taking hit the U.S. dollar, finally puncturing what ... Open-air markets in Central asia driving economic growth Central Asia's lively, open-air markets are a dead giveaway to economists: signs of a large informal sector, or "shadow economy."These ... Stock markets in Asia generally give up ground SYDNEY, Australia - Stock markets were quiet on Friday, mostly trading in negative territory.In Japan the Nikkei 225 fell 92.41 ... Google accused of spying on children ALBUQUERQUE, New Mexico - New Mexico's attorney general sued Google Thursday over allegations the tech company is illegally collecting personal ... U.S. stocks dive while greenback accelerates recent gains NEW YORK, New York - U.S. stocks weakened on Thursday but the biggest market-mover was the U.S. Dollar which soared ... Netherlands capital ponders new vision for 'red light district' PanARMENIAN.Net - Amsterdam is considering moving part of its red light district indoors to an "erotic" complex where prostitutes no ... Movie Review Sid and Nancy